Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees –
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –CENTENNIAL, Colo., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) (“Anavex” or the “Company”), announced its plan following its anticipated success in the Company’s upcoming proxy vote. PVG management is optimistic that its slate of highly
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
-- Proxy advisor recommends voting “FOR” two of PVG’s director nominees and “AGAINST” two incumbent director nominees including the board’s current chair on the GOLD Universal Proxy Card – -- PVG encourages stockholders to vote to elect all six of its director nominees by voting the GOLD Universal Proxy Card to help the Company realize the full potential of its valuable assets -- CENTENNIAL, Colo., Sept. 17, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. (“PVG”), a stockholder of 337,663 sh
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.